GE Healthcare and Valneva collaboration delivers optimised cell culture medium for vaccine production

Published: 2-Nov-2016

Viral production in EB66 cells encompasses secreted viruses, such as measles, alphaviruses, influenza A and B strains, and intracellular viruses, such as the Modified Vaccinia Ankara (MVA) virus

GE Healthcare’s Life Sciences business and Valneva SE, a fully integrated vaccine biotech company, are sharing the results of a successful collaboration to optimise virus productivity in Valneva’s EB66 cell line, a proprietary technology for the production of a wide variety of vaccines, including human and animal health vaccines.

The collaboration has resulted in the creation of a commercial cell culture medium, HyClone CDM4Avian, developed specifically to address the challenges of media variability. The new medium supports efficient and predictable virus production for manufacturers utilizing EB66 cells, helping to increase production reliability and improve end-product quality.

Suitable for use throughout the entire cell-growth process, CDM4Avian is chemically defined and free from animal-derived components, which improves product consistency and simplifies the regulatory processes for new products developed in EB66 cells.

Morgan Norris, General Manager for Upstream and Cell Culture, GE Healthcare Life Sciences, said: 'Working in close collaboration with Valneva, and capturing their expertise in vaccine production, has enabled us to successfully enhance productivity and create a novel cell culture medium for a vaccine industry undergoing a period of exciting change. The advent of cell-based production is helping manufacturers meet the growing need for vaccines to address global healthcare challenges.'

Thomas Lingelbach, President and CEO, and Franck Grimaud, Deputy CEO of Valneva, added: 'This collaboration with GE has been very successful and we are extremely pleased that our EB66 licensees now have access to a medium that will greatly ease the development of their new products. Coupled with the recent European Medicine Agency’s (EMA) decision to allow the production of live attenuated vaccines in cell-lines like EB66, this strongly supports the choice of EB66 as a modern cell technology platform for vaccine development and manufacturing.'

Until now, only inactivated vaccines could be developed in EB66 cells in Europe. The EMA recently decided to issue new guidelines on vaccine production in immortal cell lines allowing Valneva’s partners to now utilize the EB66 cell line to develop and manufacture live-attenuated vaccines (LAV), including Modified Vaccinia Ankara (MVA)-based vaccines, measles and oncolytic vaccines.

You may also like